CVE:ADK DIAGNOS (ADK) Stock Forecast, Price & News C$0.54 +0.01 (+0.94%) (As of 11:57 AM ET) Add Compare Share Share Today's RangeC$0.52▼C$0.5450-Day RangeC$0.43▼C$0.5852-Week RangeC$0.15▼C$0.59Volume35,500 shsAverage Volume116,624 shsMarket CapitalizationC$38.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsInsider TradesHeadlinesProfileChartCompetitorsEarningsInsider TradesHeadlines About DIAGNOS (CVE:ADK) StockDIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More ADK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADK Stock News HeadlinesSeptember 8, 2023 | baystreet.caDiagnos, Appulse, Bedford at 52-Week HighsJuly 15, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc down on Friday (ADK)October 3, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.July 6, 2023 | markets.businessinsider.comEchelon Wealth Partners Believes Diagnos (ADK) Won’t Stop HereMay 17, 2023 | finance.yahoo.comDIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”May 15, 2023 | baystreet.caTMX, Arrow, CPKC at 52-Week Highs on NewsMay 11, 2023 | usatoday.comMichael J. Fox: Do you have Parkinson's? New test is 'breakthrough' in diagnosing disease.May 4, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Wednesday (ADK)October 3, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.May 2, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Monday (ADK)April 28, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Thursday (ADK)April 19, 2023 | theglobeandmail.comClosing Bell: Diagnos Inc up on Tuesday (ADK)February 28, 2023 | finance.yahoo.comDIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of ContextsDecember 15, 2022 | finance.yahoo.comDIAGNOS Provides Additional Information to the Closing of Private PlacementNovember 6, 2022 | reuters.comADK.V - Diagnos Inc | Stock Price & Latest News | ReutersOctober 27, 2022 | finance.yahoo.comDIAGNOS Enters the Retinal Diagnostics Market With its New 3D Image Analysis TechnologyAugust 18, 2022 | finance.yahoo.comDIAGNOS Receives Regulatory Approval from the Costa Rica Health Agency for its Artificial Intelligence Enabled Pathology Detection SystemsJuly 27, 2022 | finance.yahoo.comDIAGNOS Continues Expansion in Canada with Kick-off of Services in Endocrinology Clinics with Distribution Partner Labtician OphthalmicsJune 7, 2022 | finance.yahoo.comDIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual GroupMay 26, 2022 | stockhouse.comDIAGNOS and the CHUM are launching the testing phase of autonomous artificial intelligence solutions dedicated to diabetic retinopathy screeningMay 12, 2022 | yahoo.comEx-attorney general Eric Holder on gerrymandering: 'Republicans have to cheat' in electionsFebruary 10, 2022 | finance.yahoo.comDIAGNOS Successfully Completes ISO / MDSAP AuditOctober 28, 2021 | nz.finance.yahoo.comDIAGNOS Delivers World Class Results in the MICCAI2021 Contest: GAMMAAugust 17, 2021 | ca.finance.yahoo.comDIAGNOS Announces Date of Annual General and Special Meeting of ShareholdersAugust 16, 2021 | stockhouse.comDIAGNOS signs Memorandum of Understanding with Essilor International.July 20, 2021 | finance.yahoo.comDIAGNOS initiates a clinical trial study in the USA for early detection and prevention of Stroke using its new application CARA-STROKEMarch 4, 2021 | finance.yahoo.comDIAGNOS and the third largest optical retailer in Costa Rica Piloting CARA and its Telemedicine technologySee More Headlines Receive ADK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ADK Company Calendar Last Earnings8/24/2023Today10/03/2023Next Earnings (Estimated)12/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE Industry Health Information Services Sub-IndustryN/A SectorMedical Current SymbolCVE:ADK CUSIPN/A CIKN/A Webwww.diagnos.ca Phone+1-450-6788882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-2,520,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-126.68% Debt Debt-to-Equity Ratio245.28 Current Ratio1.38 Quick Ratio0.68 Sales & Book Value Annual SalesC$577,486.00 Price / Sales65.72 Cash FlowC$0.01 per share Price / Cash Flow60.00 Book ValueC($0.03) per share Price / Book-17.67Miscellaneous Outstanding Shares71,610,000Free FloatN/AMarket CapC$37.95 million OptionableNot Optionable Beta-0.07 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, Pres & Exec. DirectorMr. Marc-André MassueVP of Fin., CFO & Sec.Mr. Martin BelandDirector of MarketingKey CompetitorsCloudMD Software & ServicesCVE:DOCReliq Health TechnologiesCVE:RHTVitalhubTSE:VHIViridium Pacific GroupCVE:VIRHEXOTSE:HEXOView All CompetitorsInsidersMarc-André MassueSold 1,000 sharesTotal: C$270.00 ($0.27/share)View All Insider Transactions ADK Stock - Frequently Asked Questions How have ADK shares performed in 2023? DIAGNOS's stock was trading at C$0.28 at the beginning of the year. Since then, ADK stock has increased by 89.3% and is now trading at C$0.53. View the best growth stocks for 2023 here. When is DIAGNOS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our ADK earnings forecast. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (CVE:ADK) posted its earnings results on Thursday, August, 24th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.04 million during the quarter, compared to analysts' expectations of $0.10 million. What other stocks do shareholders of DIAGNOS own? Based on aggregate information from My MarketBeat watchlists, some companies that other DIAGNOS investors own include Marijuana Company of America (MCOA), Maxar Technologies (MAXR) and Main Street Capital (MAIN). What is DIAGNOS's stock symbol? DIAGNOS trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ADK." How do I buy shares of DIAGNOS? Shares of ADK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is DIAGNOS's stock price today? One share of ADK stock can currently be purchased for approximately C$0.53. How much money does DIAGNOS make? DIAGNOS (CVE:ADK) has a market capitalization of C$37.95 million and generates C$577,486.00 in revenue each year. The company earns C$-2,520,000.00 in net income (profit) each year or C($0.04) on an earnings per share basis. How can I contact DIAGNOS? DIAGNOS's mailing address is 7005 Taschereau Blvd, Suite 340 Brossard, BROSSARD, QC J4Z 1A7, Canada. The official website for the company is www.diagnos.ca. The company can be reached via phone at +1-450-6788882. This page (CVE:ADK) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.